Losmapimod for COVID-19: real-time analysis

Download Image

Post

c19early.org

Losmapimod for COVID-19

1 study with 48 patients

Serious outcome risk

Losmapimod

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Losmapimod studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−18%

RCTs (1)−18%

Late (1)−18%

00.511.5+

← Losmapimod
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Losmapimod is an oral, small molecule anti-inflammatory drug that selectively inhibits the p38 mitogen-activated protein kinase (MAPK) pathway.


Mar 31 2021	Ziegler et al., NCT04511819	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)
Mar 31 2021	18% higher progression (p=0.54) and 14% worse recovery (p=0.64). RCT 52 hospitalized COVID-19 patients showing no significant differences with losmapimod treatment.